Inicures founders and researchers Professor Johan Bylund at the University of Gothenburg, together with Dr. Peter Olofsson-Sahl at University West, has received support from the national drug discovery platform at Scilife LAB. The lead candidates have shown strong potential, particularly for severe infections like chronic urinary tract and lung infections.With the help of DDD, they will focus on optimizing these compounds to meet industry standards. Bringing them closer to clinical use as a much-needed alternative for life-threatening infections. The current project is going very well and we have alreday treached some very promising improved pre-CD molecules and hope to be able to nominate or CD in mid 2026.
Lead optimisation support from Scilife DDD
Latest in News and Publications
Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2025) – Lyon France
Invited as presenter at the Immunotherapies & Innovations for Infectious Diseases Congress (#I4ID2025) – in Lyon, CEO of
Nordic Life Science Days 2025 Göteborg Sweden
Chairman Dr Sara Malcus and CEO Peter Olofsson-Sahl participated in the Nordic Life Science days. Reconnecting with several
Biotech Hanse Stockholm September – 2025
CEO, Peter Olofsson-Sahl presented Inicure at the #BiotechHanse event as innovative Swedish Life Science innovation for Sweden-Germany collaboration




